Zydena
In brief
- Zydena (udenafil) is sold in South Korea, Russia/CIS, the Philippines and other Asian markets and is widely available from online e‑pharmacies; officially it is prescription‑only in registered countries, but it is commonly sold in some pharmacies and online vendors without a prescription or receipt.
- Zydena is used to treat erectile dysfunction; it is a phosphodiesterase type‑5 (PDE5) inhibitor that enhances cyclic GMP–mediated smooth muscle relaxation in the penis to improve blood flow and enable an erection.
- The usual dose is 100 mg taken orally as needed before sexual activity; the maximum single dose is 200 mg and dosing should not exceed one dose per 24 hours (200 mg/day).
- The form of administration is an oral tablet (commonly 100 mg or 200 mg tablets in blister packs).
- The effect typically begins within 30–60 minutes after dosing.
- The duration of action can be up to about 12 hours, offering a longer window of effect than some other PDE5 inhibitors.
- Avoid excessive alcohol when taking Zydena — alcohol can increase dizziness, lower blood pressure, impair sexual performance and worsen side effects.
- The most common side effec is headache.
- Would you like to try zydena without a prescription?
Basic Zydena Information
- INN (International Nonproprietary Name): Udenafil
- Brand Names Available In Australia: Not specified
- ATC Code: G04BE10
- Forms & Dosages: Tablet; strengths 100 mg and 200 mg; typical blister sizes 4, 8 or 10 tablets; markets: Korea, CIS, Asia
- Manufacturers In Australia: Not specified
- Registration Status In Australia: Not specified
- OTC / Rx Classification: Prescription Only (Rx) in registered countries
Critical Warnings And Restrictions
High-Risk Groups
- Elderly patients with multiple comorbidities should get a prescriber or pharmacist review before using udenafil.
- Pregnancy and breastfeeding: the medicine is not indicated and safety is not established for women; seek medical advice.
- Patients with unstable cardiovascular disease, including recent myocardial infarction, recent stroke or unstable angina, are at high risk and must not use udenafil without specialist clearance.
- Concurrent nitrate use is an absolute contraindication because of the risk of severe hypotension.
- Severe hepatic or renal impairment is a contraindication; moderate impairment requires careful consideration.
- Patients on potent CYP3A4 inhibitors (for example some antifungals or antivirals) require prescriber review due to raised udenafil levels.
- Bleeding disorders, sickle cell disease, or a history of priapism are important cautions and need clinician assessment.
- Pre-Treatment Screening Checklist:
- Check resting blood pressure and pulse.
- Obtain a thorough cardiovascular history including recent MI, stroke or unstable angina.
- Prepare a complete current medicines list including nitrates, alpha-blockers and CYP3A4 inhibitors.
- Review recent liver and kidney function tests where available.
Emergency Advice: Priapism lasting more than four hours, sudden syncope, or severe hypotension requires urgent presentation to an emergency department.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
- Avoid driving or operating heavy machinery if feeling dizzy, light-headed, or experiencing visual disturbance after taking udenafil.
- Test your individual response at home before performing safety-critical tasks.
- Inform your employer or supervisor if a medication could impair your ability to work safely, particularly in safety-sensitive roles.
Q&A — “Can I Drive After Taking It In Australia?”
Q: Can I drive after taking udenafil?
A: Dizziness and visual disturbance are documented adverse effects with udenafil.
A: If you feel dizzy, light-headed, or have blurred vision after taking udenafil, do not drive or operate heavy machinery until you have fully recovered.
A: Australian workplace health and safety laws and road rules require that drivers and workers are fit for duty, and driving while impaired may breach duty of care.
A: Avoid driving after initial doses until you know how the medicine affects you and discuss timing with your prescriber.
Usage Basics
INN, Brand Names And International Packaging
| Brand | Strength | Typical Markets |
|---|---|---|
| Zydena | 100 mg, 200 mg | South Korea, Asia |
| Zidena | 100 mg, 200 mg | Russia, CIS |
| Udenafilo | 100 mg, 200 mg | Online/Latin markets |
Udenafil (INN) is marketed internationally under names such as Zydena, Zidena and Udenafilo.
Typical tablet strengths are 100 mg and 200 mg in blister packs of 4, 8 or 10 tablets in Asia and CIS markets.
The ATC classification G04BE10 places udenafil in the phosphodiesterase type‑5 inhibitor class used for erectile dysfunction.
Branded packaging and markets vary and online re‑labelling occurs, so verify authenticity before use.
Legal Classification (TGA, PBS)
- TGA Approval Status
- Not specified for Australia in the supplied data; check the TGA ARTG before supply.
- PBS Listing
- Not listed in the supplied data; no PBS subsidy unless formally listed.
- Prescription Requirement
- Treatment is prescription‑only in registered countries and should be treated as Rx in Australia unless a TGA listing exists.
Dosing Guide (Practical Directions)
Standard Regimens (Australian Prescriber Reference)
- Typical on‑demand initial dose is 100 mg taken orally 30–60 minutes before sexual activity.
- The maximum single dose is 200 mg and no more than one dose should be taken in any 24‑hour period.
- Daily low‑dose schedules are discussed in some markets but are not widely labelled or established as of 2025.
- Elderly patients should start at 100 mg and titrate according to tolerability and effect.
- Use with caution in mild to moderate renal impairment; severe impairment is not recommended.
- Avoid in moderate to severe hepatic impairment due to insufficient data.
- Safety Checklist Before Dosing:
- Confirm no concomitant nitrates are being used.
- Check for potent CYP3A4 inhibitors in the medication list.
- Review cardiovascular stability and baseline blood pressure.
- Advise about common adverse effects such as headache and flushing.
Adjustments For Comorbidities
- Reduce or avoid dosing triggers: advanced age with frailty, renal impairment, hepatic impairment, and the presence of potent CYP3A4 inhibitors.
- When combined with alpha‑blockers monitor for postural hypotension and stagger dosing where appropriate.
- For patients with bleeding disorders or recent peptic ulcer disease use only after specialist review.
Q&A — “What If I Miss A Dose?”
For on‑demand use, missed‑dose rules do not apply.
Take the next planned dose when appropriate but never exceed 200 mg in 24 hours.
Interaction Chart (Drugs, Food, Alcohol)
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
| Item | Interaction | Advice |
|---|---|---|
| Alcohol | May worsen dizziness and hypotension | Moderate alcohol only; avoid heavy drinking and test tolerance before driving |
| Large Meals | May delay onset of effect | Take on a lighter stomach to help onset time |
| Caffeine (coffee) | Minimal direct interaction; may mask palpitations | Use usual moderation; avoid assuming stimulation hides adverse effects |
Common Drug Conflicts
- Nitrates are an absolute contraindication due to the risk of severe, life‑threatening hypotension.
- Alpha‑blockers increase the risk of symptomatic postural hypotension; stagger dosing and monitor blood pressure.
- Potent CYP3A4 inhibitors such as ritonavir and ketoconazole will raise udenafil plasma levels and require dose adjustment or avoidance.
- Concurrent antiplatelet or anticoagulant therapy needs caution because of bleeding risk with any sexual activity‑related trauma.
- Always check a full medicines list and use a drug–interaction checker for complex regimens.
User Reports And Trends (Australia)
Australian reports are largely anecdotal but follow international themes about onset and duration.
Users commonly report an onset of around 30–60 minutes and variable duration with some claiming effects up to about 12 hours.
Common consumer comments include price sensitivity and preference for privacy and telehealth prescribing.
Online forums and ProductReview entries most often list headache, flushing and nasal congestion as typical complaints.
Patients often compare udenafil to sildenafil and tadalafil when discussing onset and duration.
Online anecdotes are not clinical evidence and should be verified with a pharmacist or GP.
| Suggested Review Sources | What To Check |
|---|---|
| ProductReview, health forums | Look for consistent batch and supplier information |
| Telehealth clinic feedback | Check for clinician verification and follow‑up |
- When Reading User Reviews, Ask:
- Which batch and supplier supplied the product?
- Were adverse effects reported and how severe were they?
- Does the seller offer an authenticity or refund policy?
- Is there independent verification that the product is from the originator manufacturer?
Access And Purchase Options In Australia
National Chains (Chemist Warehouse, Priceline, TerryWhite)
- If udenafil/Zydena is not TGA‑listed, major Australian chains are unlikely to stock it.
- Pharmacies routinely supply TGA‑approved PDE5 inhibitors such as sildenafil and tadalafil with prescription and counselling.
- PBS subsidy will not apply for non‑TGA items unless a PBS listing is confirmed.
- Major chains can provide privacy packing and pharmacist counselling for prescription PDE5 medications.
Online Pharmacies And Telehealth E-Prescriptions
- Verify a pharmacy’s Australian ABN, pharmacist contact details and TGA listing before purchase.
- Check the TGA ARTG entry for product registration if sourcing zydena or udenafil.
- Be cautious with overseas e‑pharmacies as counterfeit or mislabelled products occur.
- Consult your GP or pharmacist before importing medicines under the TGA personal importation rules.
In our online pharmacy, zydena is available without a prescription, with discreet delivery to Australia in 9-21 days.
Mechanism And Pharmacology
Simplified Explanation (Patient-Facing)
- PDE5
- An enzyme that breaks down cGMP in penile tissue.
- NO (Nitric Oxide)
- A local chemical released with sexual stimulation that starts the erection process.
- cGMP
- A molecule that causes smooth muscle relaxation and increased blood flow in the penis.
Udenafil is a selective PDE5 inhibitor that enhances nitric oxide‑mediated vasodilation in penile tissue.
It increases cGMP levels to facilitate erection in response to sexual stimulation.
Onset is typically 30–60 minutes and some reports indicate duration up to 12 hours.
Clinical Terms (Prescriber-Facing)
- ATC: G04BE10.
- Metabolism: primarily via CYP pathways with CYP3A4 predominance.
- Elimination and PK: consult the full product monograph for detailed tables and trial data.
- Adverse‑event profile is broadly similar to other PDE5 inhibitors with specific originator data from Dong‑A.
Indications And Off-Label Uses
Approved Indications By TGA (Australian Note) And By Originator Markets
| Market | Approved Indication | Year |
|---|---|---|
| South Korea | Erectile Dysfunction | Approved 2005 |
| Russia / CIS / Philippines | Erectile Dysfunction | Registered (year not specified) |
| USA / EU / Canada | Not Approved | Not Approved As Of July 2025 |
Off-Label Uses In Australian Clinical Practice
- Some PDE5 inhibitors are explored off‑label for pulmonary hypertension and lower urinary tract symptoms, but udenafil’s off‑label use is not broadly established.
- Any off‑label prescribing should be done within clinical governance, with documented informed consent and monitoring.
- Prefer established, TGA‑approved alternatives for conditions outside labelled ED indications.
Key Clinical Findings (Efficacy & Safety)
- Onset commonly reported at 30–60 minutes after oral dosing.
- On‑demand dosing is effective with single doses up to 200 mg and a maximum of one dose per 24 hours.
- Common adverse events include headache, flushing, nasal congestion, dyspepsia, back pain and dizziness.
- Transient visual changes are rare and reportedly less frequent than with sildenafil.
- Long‑term safety data outside Korea and CIS are limited; Australian prescribers should be cautious with imported or non‑registered use.
Suggestion: Consider a short evidence table in clinical notes summarising key trials, year and outcomes for ease of reference during consultations.
Alternatives Matrix (Comparison With PBS Options)
PBS-Listed Alternatives Comparison Table
| Drug | Onset | Duration | PBS Status | Common AEs |
|---|---|---|---|---|
| Udenafil (Zydena) | 30–60 min | Up to ~12 hours reported | Not specified / likely not PBS if not TGA listed | Headache, flushing, nasal congestion |
| Sildenafil (Viagra) | 30–60 min | ~4–6 hours | Some formulations PBS listed under specific conditions | Headache, flushing, dyspepsia, visual changes |
| Tadalafil (Cialis) | 30 min | Up to 36 hours | Some formulations PBS listed under specific conditions | Back pain, myalgia, headache |
| Vardenafil (Levitra) | ~25–60 min | ~4–6 hours | Not commonly PBS listed | Headache, flushing |
| Avanafil (Spedra) | ~15–30 min (faster) | ~6 hours | Not commonly PBS listed | Headache, flushing |
Pros And Cons Checklist
- Efficacy: similar class effects; individual response varies and may favour one agent over another.
- Duration: udenafil reports longer duration than sildenafil in some accounts; tadalafil generally lasts longer than most.
- Cost: PBS subsidy may favour sildenafil or tadalafil depending on listing and patient concession status.
- TGA / PBS Status: verified local approval and subsidy greatly affect access and counselling obligations.
- Access: imported udenafil may be cheaper but carries authenticity and regulatory risks.
- Safety Monitoring: local alternatives have stronger local post‑marketing surveillance in Australia.
Common Questions (Australian Pharmacy Consultations)
- “Is it safe with my heart tablets?” → If you are on nitrates it is absolutely contraindicated; review alpha‑blockers and antihypertensives with your prescriber.
- “How long before sex?” → Typically 30–60 minutes.
- “Can I drink alcohol?” → Use moderate amounts only and avoid heavy drinking due to added hypotension risk.
- “Is it on the PBS?” → Only if TGA/PBS listed; check the current PBS schedule as imported products are unlikely to be subsidised.
- “What if I get an erection lasting more than four hours?” → Seek emergency care immediately for priapism.
- Document counselling and recommend GP review for first‑time users and complex medical histories.
Price And Access Comparison (Practical Table & Checklist)
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Status, Prescription Required
| Pharmacy Source | Typical Price Range | PBS Status | Prescription Required |
|---|---|---|---|
| In‑Store Major Chains (Australia) | Varies by brand; PBS pricing applies for listed items | PBS applies to listed formulations only | Yes |
| Online Australian Pharmacies | Competitive; includes telehealth consult options | PBS applies if product is TGA/PBS listed | Yes |
| Overseas E‑Shops | Often lower advertised prices | Not PBS subsidised | Usually ships without Australian prescription; import rules apply |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Verify TGA listing and ARTG number before supply.
- Ensure the pharmacy has a registered pharmacist contact and Australian ABN.
- Check delivery times and privacy packaging options.
- Verify returns and authenticity policies for high‑value purchases.
- Rural patients should confirm stock availability and consider telehealth prescription services for convenience.
Registration And Regulation
TGA Approval
- Check the Australian Register of Therapeutic Goods (ARTG) to confirm whether udenafil or Zydena is registered for supply.
- If the product is not ARTG‑listed it is not an approved therapeutic good for general supply in Australia.
- Prescribers and pharmacists must verify ARTG status prior to recommending or supplying imported preparations.
PBS Subsidy Details And Personal Importation Scheme
- PBS Listing Process
- PBS listing requires TGA registration and an independent assessment for subsidy; without listing no subsidy applies.
- Personal Importation Notes
- Personal importation can permit limited private imports (commonly up to 3 months’ supply) but patients must comply with TGA and customs rules and consult their GP or pharmacist.
Storage And Handling (Household And Pharmacy)
Household Storage In Australian Climate (Heat/Humidity)
- Store below 25°C and protect from moisture and direct sunlight.
- Avoid storing tablets in bathrooms or cars where heat and humidity spike.
- Keep in the original packaging to protect from light and to retain batch information.
- Keep all medicines out of reach of children and pets.
Cold-Chain Handling For Pharmacies
- Udenafil tablets do not require cold chain storage but should be transported in temperature‑stable, tamper‑evident packaging.
- Follow pharmacy SOPs for ambient controlled storerooms and stock rotation.
- Record storage temperatures and train staff on tamper checks and dispatch documentation.
Guidelines For Proper Use (Pharmacist Counselling And Patient Advice)
Australian Pharmacist Counselling Style (What To Cover)
- Screening questions: cardiovascular history, current nitrate use, liver and kidney disease, and bleeding risks.
- Dosing instructions: start 100 mg 30–60 minutes before sex, max 200 mg in 24 hours.
- Interaction review: check for CYP3A4 inhibitors and alpha‑blockers and advise on timing.
- Red flags: persistent erection over four hours, chest pain, sudden vision loss or hearing loss; seek urgent care.
- Document consent and provide written safety points and follow‑up advice.
Patient Advice From PBS And National Health Authorities
- Report any suspected adverse events to the TGA via the Therapeutic Goods Reporting System.
- Follow up with your GP for review if you have ongoing use, new medications or worsening health.
- Verify product registration status with the TGA and avoid unverified overseas suppliers when possible.
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 9-14 days |
| Sunshine Coast | Queensland | 14-21 days |
| Geelong | Victoria | 14-21 days |
| Darwin | Northern Territory | 14-21 days |
| Cairns | Queensland | 14-21 days |
| Townsville | Queensland | 14-21 days |
Registration And Regulation Continued
TGA Approval
- Before prescribing or supplying udenafil check the ARTG for an authorised Zydena or udenafil entry.
- Non‑ARTG items are not approved for general supply and carry regulatory considerations for supply and importation.
PBS Subsidy Details And Personal Importation Scheme
- PBS Listing
- No PBS subsidy applies unless the product files and is accepted for listing.
- Personal Importation
- Patients may import limited supplies for personal use under the TGA personal importation scheme but should consult a GP or pharmacist first.
Storage And Handling Recap
Household Storage
- Keep below 25°C, in original packaging, and out of bathrooms and cars.
- Protect from direct sunlight and moisture to preserve tablet integrity.
Pharmacy Handling
- Transport in tamper‑evident packaging and store under ambient controlled conditions per SOP.
- Record temperature logs and ensure clear labelling with batch information.
Guidelines For Proper Use Summary
Pharmacist Counselling Checklist
- Screen cardiovascular status, check for nitrate use and CYP3A4 interactions.
- Advise 100 mg initial dose, 30–60 minutes before sex, max 200 mg in 24 hours.
- Explain common side effects and urgent red flags such as priapism and sudden visual changes.
- Provide written advice and document counselling in the patient record.
Patient Advice
- Report adverse events to the TGA and follow up with the GP for ongoing use.
- Verify TGA registration before sourcing overseas products and avoid unverified suppliers.
Final Notes For Clinicians And Patients
Udenafil is a PDE5 inhibitor with an efficacy and safety profile similar to other agents in its class but with limited long‑term data outside Asia and CIS markets.
Use established, locally approved PDE5 inhibitors where possible and consider udenafil only after verifying registration status and product authenticity.
Report any suspected adverse events to the TGA and document all counselling and clinical rationale for off‑label or imported use.